Cargando…

Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry

BACKGROUND: Dyskalemia is a mortality risk factor in patients with heart failure (HF). HYPOTHESIS: We described the prevalence of dyskalemia, and clinical outcomes by serum potassium (sK) levels, in Chinese patients hospitalized for HF. METHODS: In this secondary analysis of the prospective China Na...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jingmin, Jin, Xuejuan, Zhou, Jun, Xu, Yamei, Cui, Xiaotong, Fu, Michael, Hu, Kai, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642319/
https://www.ncbi.nlm.nih.gov/pubmed/37577821
http://dx.doi.org/10.1002/clc.24114
_version_ 1785146941517070336
author Zhou, Jingmin
Jin, Xuejuan
Zhou, Jun
Xu, Yamei
Cui, Xiaotong
Fu, Michael
Hu, Kai
Ge, Junbo
author_facet Zhou, Jingmin
Jin, Xuejuan
Zhou, Jun
Xu, Yamei
Cui, Xiaotong
Fu, Michael
Hu, Kai
Ge, Junbo
author_sort Zhou, Jingmin
collection PubMed
description BACKGROUND: Dyskalemia is a mortality risk factor in patients with heart failure (HF). HYPOTHESIS: We described the prevalence of dyskalemia, and clinical outcomes by serum potassium (sK) levels, in Chinese patients hospitalized for HF. METHODS: In this secondary analysis of the prospective China National Heart Failure Registry, adult patients hospitalized between January 1, 2013 and June 30, 2015 who had at least one baseline sK measurement were followed for up to 3 years after discharge. The use of renin–angiotensin–aldosterone system inhibitors at baseline and clinical outcomes during follow‐up were compared among sK groups. RESULTS: Among 6950 patients, 5529 (79.6%) had normokalemia (sK >3.5–5.0 mmol/L), 1113 (16.0%) had hypokalemia (sK 0–3.5 mmol/L), and 308 (4.4%) had hyperkalemia (sK >5.0 mmol/L). Baseline characteristics that were most common in patients with hyperkalemia than those with hypo‐ and normokalemia included older age, HF with reduced ejection fraction, New York Heart Association Class III/IV status, hypertension, and chronic kidney disease. Use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) differed across sK groups (p = .0001); reported in 64.1%, 63.4%, and 54.5% of patients with hypo‐, normo‐, and hyperkalemia, respectively. Overall, 26.6%, 28.6%, and 36.0% of patients with hypo‐, normo‐, and hyperkalemia had rehospitalization for worsened HF, or cardiovascular mortality; p = .0057 for between‐group comparison. CONCLUSIONS: Patients with hyperkalemia received ACEIs or ARBs for HF treatment at baseline less frequently than those with hypo‐ or normokalemia, and had worse prognoses. This warrants further investigation into effective hyperkalemia management in HF.
format Online
Article
Text
id pubmed-10642319
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106423192023-11-15 Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry Zhou, Jingmin Jin, Xuejuan Zhou, Jun Xu, Yamei Cui, Xiaotong Fu, Michael Hu, Kai Ge, Junbo Clin Cardiol Clinical Investigations BACKGROUND: Dyskalemia is a mortality risk factor in patients with heart failure (HF). HYPOTHESIS: We described the prevalence of dyskalemia, and clinical outcomes by serum potassium (sK) levels, in Chinese patients hospitalized for HF. METHODS: In this secondary analysis of the prospective China National Heart Failure Registry, adult patients hospitalized between January 1, 2013 and June 30, 2015 who had at least one baseline sK measurement were followed for up to 3 years after discharge. The use of renin–angiotensin–aldosterone system inhibitors at baseline and clinical outcomes during follow‐up were compared among sK groups. RESULTS: Among 6950 patients, 5529 (79.6%) had normokalemia (sK >3.5–5.0 mmol/L), 1113 (16.0%) had hypokalemia (sK 0–3.5 mmol/L), and 308 (4.4%) had hyperkalemia (sK >5.0 mmol/L). Baseline characteristics that were most common in patients with hyperkalemia than those with hypo‐ and normokalemia included older age, HF with reduced ejection fraction, New York Heart Association Class III/IV status, hypertension, and chronic kidney disease. Use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) differed across sK groups (p = .0001); reported in 64.1%, 63.4%, and 54.5% of patients with hypo‐, normo‐, and hyperkalemia, respectively. Overall, 26.6%, 28.6%, and 36.0% of patients with hypo‐, normo‐, and hyperkalemia had rehospitalization for worsened HF, or cardiovascular mortality; p = .0057 for between‐group comparison. CONCLUSIONS: Patients with hyperkalemia received ACEIs or ARBs for HF treatment at baseline less frequently than those with hypo‐ or normokalemia, and had worse prognoses. This warrants further investigation into effective hyperkalemia management in HF. John Wiley and Sons Inc. 2023-08-14 /pmc/articles/PMC10642319/ /pubmed/37577821 http://dx.doi.org/10.1002/clc.24114 Text en © 2023 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigations
Zhou, Jingmin
Jin, Xuejuan
Zhou, Jun
Xu, Yamei
Cui, Xiaotong
Fu, Michael
Hu, Kai
Ge, Junbo
Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title_full Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title_fullStr Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title_full_unstemmed Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title_short Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
title_sort clinical outcomes by serum potassium levels for patients hospitalized for heart failure: secondary analysis of data from the china national heart failure registry
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642319/
https://www.ncbi.nlm.nih.gov/pubmed/37577821
http://dx.doi.org/10.1002/clc.24114
work_keys_str_mv AT zhoujingmin clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT jinxuejuan clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT zhoujun clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT xuyamei clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT cuixiaotong clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT fumichael clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT hukai clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT gejunbo clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry
AT clinicaloutcomesbyserumpotassiumlevelsforpatientshospitalizedforheartfailuresecondaryanalysisofdatafromthechinanationalheartfailureregistry